已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation

封锁 癌症研究 抗体 单克隆抗体 免疫疗法 效力 体内 癌症免疫疗法 免疫系统 免疫检查点 体外 医学 T细胞 黑色素瘤 PD-L1 癌症 受体 药理学 化学 免疫学 生物 内科学 生物化学 生物技术
作者
Hui Yuwen,Tengteng Li,Yijing Ren,Dirk Hoenemann,Jay M. Mei,Bo Shan,Bing Hou
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A936-A937 被引量:4
标识
DOI:10.1136/jitc-2021-sitc2021.893
摘要

Background Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1(PD-1) blockade therapy has revolutionized the treatment landscape of malignancies. However, only a minority of patients are anticipated to experience a deep and durable response. In addition, successful therapeutic agonism of 4-1BB, a promising co-stimulatory immunologic target, has been limited by major safety concerns of hepatotoxicity or suboptimal agonistic potency. ATG-101, a novel PD-L1/4-1BB bispecific antibody, was designed to activate 4-1BB positive T cells in a PDL1-crosslinking dependent manner and to effectively treat tumors without on-target-off-tumor liver toxicity (figure 1). Methods ATG-101 was developed by introducing lower affinity 4-1BB scFv into a human IgG1 PD-L1 monoclonal antibody. The N297A mutation on CH2 abolishes the binding capacity to most FcγRs but retains the binding to FcγRn. A series of in vitro and in vivo studies were performed to evaluate the potency, safety and specific mechanism of action. Results ATG-101 simultaneous binds to 4-1BB and PD-L1 with higher affinity to PD-L1, and potently activates 4-1BB positive T cells when crosslinked by PD-L1 positive cells. Upon crosslinking, ATG-101 also activates PD1+TIM3+ exhausted T cells in vitro, suggesting a potential in reversing T-cell dysfunction and exhaustion (figure 1). ATG-101 shows potent anti-tumor activities in various animal models, including h4-1BB humanized mice bearing MC38 colon cancer, PD(L)1 blockade insensitive B16F10 melanoma and EL4 lymphoma, with no body weight loss observed. To evaluate ATG-101 efficacy in tumors progressing after anti-PD(L)1 treatment, mice bearing MC38 tumors were treated with anti-PDL1 initially to achieve tumor growth inhibition, and half of the mice switched to ATG-101 upon disease progression, the other mice continuing with anti-PD-L1 treatment. ATG-101 induced potent tumor growth inhibition and tumor regression in anti-PDL1-resistant tumors and prolonged survival. Flow cytometry and multiplex IHC staining of tumor samples from mice treated with ATG-101 or control suggest that ATG-101 increases the infiltration, proliferation and activation of CD8+ T cells (figure 2), the infiltration of natural killer T cells and the CD8+/Treg ratio in TILs. In a 4-week GLP toxicity study in cynomolgus monkey, up to 100mg/kg repeated doses of ATG-101 were well tolerated with no hepatotoxicity observed. Conclusions ATG-101 demonstrated significant anti-tumor activity in various tumor models including those progressing on anti PD(L)1 treatment. Good safety and PK/PD properties has been demonstrated in preclinical in vivo models. A phase I, multicenter, dose-escalating clinical trial evaluating ATG-101 in patients with solid tumors and hematologic malignancies is ongoing. Ethics Approval The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio or Innostar prior to execution with an AUP number or IACUC approval number for each animal study. During the study, the care and use of animals were conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).All studies were conducted following an approved IACUC protocol. AUP NO.:2004-12-1465, 2004-12-1000; IACUC approval number: IACUC-2021-M-003
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
coco仓完成签到 ,获得积分10
刚刚
1秒前
3秒前
668898发布了新的文献求助10
4秒前
方九九发布了新的文献求助10
5秒前
小王发布了新的文献求助10
5秒前
6秒前
一块麻糖发布了新的文献求助10
7秒前
852的应助被Karry采纳,获得10
8秒前
8秒前
KK完成签到,获得积分10
9秒前
wczkzzyfxh完成签到,获得积分10
9秒前
Jun的应助被屈狒狒采纳,获得10
10秒前
10秒前
xiuxiuzhang发布了新的文献求助10
10秒前
11秒前
小宋完成签到 ,获得积分10
11秒前
zzcs33发布了新的文献求助10
11秒前
酷波er的应助被大意的访旋采纳,获得10
11秒前
方九九完成签到,获得积分10
12秒前
13秒前
如意的一刀完成签到 ,获得积分10
13秒前
余香的应助被wydkyd采纳,获得10
13秒前
踏实香氛发布了新的文献求助10
13秒前
无极微光的应助被sang采纳,获得20
14秒前
科研马发布了新的文献求助10
15秒前
CCCms关注了科研通微信公众号
15秒前
小马甲的应助被hehe采纳,获得10
16秒前
无w完成签到,获得积分10
16秒前
17秒前
chunyan_li发布了新的文献求助100
18秒前
淡淡班完成签到 ,获得积分10
18秒前
哈哈哈哈哈哈完成签到 ,获得积分10
19秒前
zhangqi完成签到,获得积分10
20秒前
LWW发布了新的文献求助10
21秒前
23秒前
taku完成签到 ,获得积分0
23秒前
24秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158064
求助须知:如何正确求助?哪些是违规求助? 9553987
关于积分的说明 21716926
捐赠科研通 7747422
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471057